 It is a KOR agonist and MOR partial agonist, and also has high affinity for the DOR.Research into the use of cyclazocine for the treatment of bipolar patients with depression was undertaken by Fink and colleagues (1970).It showed that 8 out of 10 patients experienced moderate improvement.